Komori
Presentation materials for financial results4483JMDC Inc.Information and Communications, Services and Others

Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027

In the first quarter of the fiscal year ending March 2027, revenue and profit both exceeded the year-earlier period and initial expectations, driven by stronger demand from industry customers and the early recognition of revenue from certain projects. The full-year forecast was unchanged, while a first-half forecast was newly disclosed.

Worth reading
61In focus
Scored from 4 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
18
Year-on-year change in revenue (%)
Wording
Conditional
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFirst quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥12,605 million+18.0%
Operating profit¥1,823 million+17.0%
Ordinary income¥1,688 millions +17.0%IFRS, profit before tax
Net income¥1,131 millions +17.0%profit attributable to owners of the parent
Operating profit margin15 %
Results for the three months of the current quarter
Revenue
¥12,605 million
Operating profit
¥1,823 million
Income before taxes
¥1,688 million
Profit attributable to owners of the parent
¥1,131 million
EBITDA
¥2,663 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
A good start, exceeding initial expectations
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Demand from industry customers exceeding expectations
  • Revenue recognition for certain projects brought forward from Q2 to Q1400 approximately million yen
  • Recovery in demand from the Medical division
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • 400 approximately million yen
    AssumptionsAmount of revenue brought forward from certain projects
  • 23 %
    AssumptionsFirst-half EBITDA margin
  • 24 %
    AssumptionsYear-earlier first-half EBITDA margin
New initiatives
  • Disclosure of a first-half earnings forecast
Key KPIsA metric the company considers important as a management benchmark.
  • Transaction value of data utilization for industry customers¥4,592 million+26.0%
  • Business scale serving insurers and consumers¥1,856 million+4.0%
  • Business scale serving healthcare providers¥4,571 million+20.0%
  • Transaction value with the Medical divisionAmount not stated+26.0%
  • Number of contracted medical institutions1,700 Facility
  • Number of contracted radiologists1,300 people
  • Industry share30 %
Segment results
  • Health Big Data
    Sales¥10,955 million (YoY +19.0%)
    EBITDA¥2,250 million (YoY +17.0%)
    EBITDA margin21 %
  • Telemedicine
    Sales¥1,649 million (YoY +8.0%)
    EBITDA¥653 million (YoY +22.0%)
    EBITDA margin40 %
  • Adjustments
    Sales¥0 million
    EBITDA¥-240 million
Market Size / Share
  • Number of medical facilities in Japan110,000 Approximately facilities
  • Number of imaging examinations150,000,000 Cases/year
  • Number of radiologists6,000 approximately people
  • Telemedicine industry market share30 Approximately %
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFirst quarter of the fiscal year ending March 2027
Net Sales¥12,605 million (YoY +18.0%)
Operating profit¥1,823 million (YoY +17.0%)
Ordinary income¥1,688 millions (IFRS, profit before tax) (YoY +17.0%)
Net income¥1,131 millions (profit attributable to owners of the parent) (YoY +17.0%)
Operating profit margin15 %
Results for the three months of the current quarterRevenue ¥12,605 million / Operating profit ¥1,823 million / Income before taxes ¥1,688 million / Profit attributable to owners of the parent ¥1,131 million / EBITDA ¥2,663 million
Self-assessment against the planA good start, exceeding initial expectations
Segment resultsSegment Health Big Data / Sales ¥10,955 million (YoY +19.0%) / EBITDA ¥2,250 million (YoY +17.0%) / EBITDA margin 21 %, Segment Telemedicine / Sales ¥1,649 million (YoY +8.0%) / EBITDA ¥653 million (YoY +22.0%) / EBITDA margin 40 %, Segment Adjustments / Sales ¥0 million / EBITDA ¥-240 million
Breakdown of Factors Affecting the ChangeFactors Demand from industry customers exceeding expectations / Amount Not disclosed, Factors Revenue recognition for certain projects brought forward from Q2 to Q1 / Amount 400 approximately million yen, Factors Recovery in demand from the Medical division / Amount Not disclosed
Key KPIsTransaction value of data utilization for industry customers ¥4,592 million (YoY +26.0%), Business scale serving insurers and consumers ¥1,856 million (YoY +4.0%), Business scale serving healthcare providers ¥4,571 million (YoY +20.0%), Transaction value with the Medical division 非開示 (YoY +26.0%), Number of contracted medical institutions 1,700 Facility, Number of contracted radiologists 1,300 people, Industry share 30 %
Assumptions Underlying the Business Outlook400 approximately million yen, 23 %, 24 %
Market Size / Share110,000 Approximately facilities, 150,000,000 Cases/year, 6,000 approximately people, 30 Approximately %
New initiativesDisclosure of a first-half earnings forecast
Items this document does not state (16)
Gross Profit MarginSelling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The main reasons were stronger-than-expected demand from industry customers, particularly pharmaceutical companies; a recovery in demand from the Medical division; and the delivery and revenue recognition of certain projects being brought forward from Q2 to Q1 (approximately ¥400 million).

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027 | JMDC Inc. (4483) timely disclosure | Komori